Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
| 适应症 | Prostate Cancer, Prostatic Adenocarcinoma |
|---|---|
| 分期 | 不适用 |
| 申办方 | Memorial Sloan Kettering Cancer Center |
| 状态 | 已完成 |
| 受试者人数 | 41 人 |
| 干预（药物） | degarelix injection, degarelix injection, androgen deprivation therapy |
| 开始日期 | 2012年2月24日 |
| 完成日期 | 2024年9月30日 |
| 结果公布日 | 2026年7月29日 |
摘要
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has been no proven benefit with this approach. The investigators do not expect the patient to benefit directly from treatment with degarelix since their prostate will be removed shortly after the drug is given. Instead, the investigators hope to learn about how degarelix and other treatment that lowers your testosterone effects prostate cancer cells and use this information to develop better treatments in the future.
Percent Change in Prostate Cancer Cell Proliferation (Ki-67 Levels)
| Untreated Patients Degarelix Injection Occur at Days 4± 1 | 32 percent change |
|---|---|
| Untreated Patients Degarelix Injection Occur at Days and 7± 1. | 27 percent change |
| Untreated Patients With Androgen Deprivation | 88 percent change |
| Untreated Patients Degarelix Injection Occur at Days 14±1 | NA percent change |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
- Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery — Wake Forest University Health Sciences
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
- M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)